<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; KG</title>
	<atom:link href="http://www.stockbloghub.com/tag/kg/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PFE) Pfizer Extends King Pharmaceuticals Stock Tender Offer</title>
		<link>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660</link>
		<comments>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:49:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65660</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently announced that it has extended the expiration date of its tender offer for all outstanding shares of King Pharmaceuticals, Inc. (KG) by 7 days. The tender offer is now set to expire on January 28, 2011. As of January 20, 2011, about 46.6% of King Pharma’s outstanding shares were validly tendered. Acquisition Deal Announced in October 2010 Pfizer had initially announced its intention to acquire King Pharma on October 12, 2010 for $14.25 per share. The offer price represents a 40% premium to King Pharma’s closing price on Oct 11, 2010. At the time of announcing the acquisition, Pfizer had said that it expects the deal to boost its 2011 and 2012 earnings by 2 cents annually and 2013 – 2015 earnings by 3-4 cents annually. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Files New Drug Application for Pain Drug</title>
		<link>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195</link>
		<comments>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195#comments</comments>
		<pubDate>Tue, 28 Dec 2010 00:02:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63195</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for providing relief from moderate to severe pain. Acurox has been developed using Acura’s Aversion technology. King Pharma is seeking priority review for the candidate. King Pharma and Acura had also submitted a new drug application seeking approval for Acurox (with niacin) for which the companies received a Complete Response Letter (CRL) on June 30, 2009. Based on discussions with the FDA, King Pharma and Acura submitted the NDA to an FDA advisory panel. However, earlier this year, the FDA panel voted that they did not have sufficient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-files-new-drug-application-for-pain-drug/63195/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Files New Drug Application for Pain Drug</title>
		<link>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265</link>
		<comments>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265#comments</comments>
		<pubDate>Mon, 27 Dec 2010 16:15:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63265</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for providing relief from moderate to severe pain. Acurox has been developed using Acura’s Aversion technology. King Pharma is seeking priority review for the candidate. King Pharma and Acura had also submitted a new drug application seeking approval for Acurox (with niacin) for which the companies received a Complete Response Letter (CRL) on June 30, 2009. Based on discussions with the FDA, King Pharma and Acura submitted the NDA to an FDA advisory panel. However, earlier this year, the FDA panel voted that they did not have sufficient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/kg-king-pharmaceuticals-and-acura-pharmaceuticals-files-new-drug-application-for-pain-drug/63265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Quarterly Earnings Report Disappoints</title>
		<link>http://www.stockbloghub.com/2010/11/17/kg-king-pharmaceuticals-quarterly-earnings-report-disappoints/58453</link>
		<comments>http://www.stockbloghub.com/2010/11/17/kg-king-pharmaceuticals-quarterly-earnings-report-disappoints/58453#comments</comments>
		<pubDate>Thu, 18 Nov 2010 04:42:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58453</guid>
		<description><![CDATA[In a filing with the US Securities and Exchange Commission (SEC), King Pharmaceuticals Inc. (KG) reported third-quarter earnings of 16 cents per share, a penny below the year-ago earnings. The Zacks Consensus Estimate was 19 cents. Revenues fell 19.2% to $374.5 million mainly due to the lackluster performance of several key products and the entry of two generic versions of Skelaxin. Revenues, however, exceeded the Zacks Consensus Estimate by $7.5 million. Quarter in Detail King Pharma&#8217;s branded Pharmaceuticals segment declined 43.3% with revenues coming in at $160.8 million. Revenues of almost all key products declined from the year-ago period. Thrombin-JMI sales declined 25.9% to $32.2 million. We expect Thrombin-JMI sales to continue declining due to tough competition in the form of Bristol-Myers Squibbs’ (BMY) Recothrom and Johnson &#38; Johnson’s (JNJ) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/kg-king-pharmaceuticals-quarterly-earnings-report-disappoints/58453/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Biocon Enter Gloabal Diabetes Deal</title>
		<link>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694</link>
		<comments>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694#comments</comments>
		<pubDate>Wed, 20 Oct 2010 05:28:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55694</guid>
		<description><![CDATA[Pfizer (PFE) recently entered into a global agreement with Indian biotech company Biocon, for certain diabetes biosimilars. The deal relates to the global commercialization of biosimilar versions of insulin and insulin analog products like recombinant human insulin, glargine, aspart and lispro. Terms of the Deal Per the terms of the deal, Pfizer will commercialize these products across the world excluding certain territories. The company will share commercialization rights with Biocon for all these products in Germany, India and Malaysia. In case of several developing markets, Pfizer will share commercialization rights with existing licensees. Biocon will be responsible for developing, manufacturing, supplying and gaining regulatory approval for these products. We note that Biocon’s version of recombinant human insulin is already approved in 27 developing markets. Meanwhile, the biosimilar version of Sanofi-Aventis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/19/pfe-pfizer-and-biocon-enter-gloabal-diabetes-deal/55694/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals&#8217; Quarterly Report Disappoints &#8211; Revenues Slide</title>
		<link>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255</link>
		<comments>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255#comments</comments>
		<pubDate>Wed, 05 May 2010 21:06:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36255</guid>
		<description><![CDATA[King Pharmaceuticals Inc (KG) reported first-quarter earnings of 14 cents per share, well below the Zacks Consensus Estimate of 24 cents and the year-ago earnings of 26 cents. Revenues fell 11.2% from the year-ago quarter to $380.9 million. The Quarter in Detail King&#8217;s branded Pharmaceuticals segment declined 12.9% with revenues coming in at $242 million. Revenues of all key products excluding Flector Patch declined from the year-ago period. Thrombin-JMI sales declined to $37 million, down 21.3%. We expect Thrombin-JMI sales to continue declining due to the tough competition in the form of ZymoGenetics&#8216; (ZGEN) Recothrom and Omrix Biopharmaceuticals&#8216; (OMRI) Evithrom. Meanwhile, Skelaxin, which posted sales of $91 million (down 9.9%), is facing stiff competition from Cephalon&#8216;s (CEPH) Amrix. Amrix&#8217;s once-daily dosing regime and low rate of somnolence should provide it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/kg-king-pharmaceuticals-quarterly-report-disappoints-revenues-slide/36255/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Announces FDA Panel Votes Against Acurox</title>
		<link>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018</link>
		<comments>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018#comments</comments>
		<pubDate>Tue, 27 Apr 2010 17:40:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35018</guid>
		<description><![CDATA[The US Food and Drug Administration’s (FDA) advisory panel recently withheld the approval for opioid candidate, Acurox, used in treating moderate to severe pain. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The candidate has been developed as per King Pharmaceuticals, Inc.’s (KG) agreement with Acura Pharmaceuticals, Inc. (ACUR) for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The advisory panel’s opposition to the approval does not come as a surprise. Earlier in June 2009, King and Acura had received a complete response letter from the FDA regarding the New Drug Application (NDA) for Acurox. At that time, the FDA had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/27/kg-king-pharmaceuticals-announces-fda-panel-votes-against-acurox/35018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PTIE) Pain Therapeutics Sees Encouraging Data on PTI-188</title>
		<link>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687</link>
		<comments>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:28:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31687</guid>
		<description><![CDATA[Pain Therapeutics, Inc. (PTIE) recently presented encouraging data on its metastatic melanoma candidate, PTI-188. The company said that the administration of a single dose of PTI-188, a radio-labeled monoclonal antibody, resulted in the stabilization or decrease in the size of a number of melanoma tumors. In one of the phase I studies, about 70% of the patients showed stable disease in target lesions at the end of six weeks. The second phase I study showed that about 40% of the patients showed stable disease at week fourteen. PTI-188 was well-tolerated at all doses. Preliminary analysis showed that the median overall survival time based on data from both the studies was 13 months. This represents an improvement over the current median survival time of 9 months in metastatic melanoma patients. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Learn FDA to Review Acurox</title>
		<link>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216</link>
		<comments>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31216</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently announced that the FDA has established a date for an advisory committee meeting which will discuss the new drug application for Acurox. The committee will also discuss the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone. The meeting, scheduled to take place on April 22, will be a joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The drug has been developed under King’s agreement with Acura Pharmaceuticals for the licensing, development, and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/kg-king-pharmaceuticals-and-acura-pharmaceuticals-learn-fda-to-review-acurox/31216/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals and Acura Pharmaceuticals Report Positive Data on Acurox Study</title>
		<link>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181</link>
		<comments>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181#comments</comments>
		<pubDate>Tue, 09 Mar 2010 22:41:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30181</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently presented positive top-line data on opioid candidate Acurox from a study that was conducted to assess the relative abuse potential of the drug. Results from Study AP-ADF-114 (A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users) showed that Acurox was significantly disliked compared to oxycodone HCl tablets alone when excess doses are swallowed. All five co-primary endpoints of the study were achieved. Acurox is an orally administered tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. The drug has been developed under King’s agreement with Acura Pharmaceuticals for the licensing, development, and commercialization ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/09/kg-king-pharmaceuticals-and-acura-pharmaceuticals-report-positive-data-on-acurox-study/30181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Misses Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115</link>
		<comments>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115#comments</comments>
		<pubDate>Mon, 01 Mar 2010 04:15:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29115</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported fourth-quarter earnings of 23 cents per share, a penny below the Zacks Consensus Estimate. Despite fourth quarter revenues increasing 26.1% from the year-ago period, earnings declined 20.6% from the year-ago quarter, mainly due to higher operating expenses. Full-year earnings, which came in a couple of cents above the Zacks Consensus Estimate at $1.10, declined 28.6% from the year-ago period. Meanwhile, full-year revenues increased 14% to $1.78 billion. Fourth-Quarter Performance Fourth-quarter revenues came in at $439.1 million. King&#8217;s branded pharmaceuticals segment remained flat with revenues coming in at $277 million. While Avinza revenues remained flat, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $44 million, down 22.8%. We expect Thrombin-JMI sales to continue declining due to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($KG) King Pharmaceuticals Beats Consensus, but Earnings Down</title>
		<link>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827</link>
		<comments>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:35:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19827</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business. King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the prior-year period. While generic versions of Altace continued to impact the top-line, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $43 million, down 35.8%. We expect Thrombin-JMI sales to continue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Launches Embeda for Around-The-Clock Pain Relief</title>
		<link>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013</link>
		<comments>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:39:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corp.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16013</guid>
		<description><![CDATA[Earlier this week, King Pharmaceuticals, Inc. (KG) announced the launch of Embeda, which recently received U.S. Food and Drug Administration (FDA) approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda, which is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing, will be available in six dosage strengths. As per the requirement of the FDA, the company has also implemented a Risk Evaluation and Mitigation Strategy (REMS) under which patients and providers will be informed about the potential for abuse, misuse, overdose, and addiction of Embeda and about the safe use of the opioid. The approval and launch of Embeda is a significant milestone for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) ZymoGenetic&#8217;s Arthritis Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016</link>
		<comments>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016#comments</comments>
		<pubDate>Fri, 11 Sep 2009 22:47:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15016</guid>
		<description><![CDATA[Yesterday, ZymoGenetics Inc (ZGEN) announced that its rheumatoid arthritis drug Atacicept, failed to reach its goal of controlling the disease in mid-stage studies. The data did not support a direct move to late-stage trials. However, the study confirmed the biological effect of Atacicept, and did not display any unexpected side effects. Atacicept is being developed in collaboration with Merck Serono S.A. (formerly Serono S.A.), an affiliate of Merck KGaA, Darmstadt, Germany.  Under this agreement, ZymoGenetics will co-promote Atacicept with Merck Serono in the US, while Merck Serono will promote Atacicept ex-US. In view of the disappointing results, Merck Serono has not decided whether the late-stage trials will be conducted. Atacicept is also being developed for other indications such as lupus and multiple sclerosis. As a reminder, Recombinant human thrombin (rhThrombin, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) FDA Advisory Panel to Review Acurox</title>
		<link>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484</link>
		<comments>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484#comments</comments>
		<pubDate>Fri, 04 Sep 2009 22:54:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14484</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently met with the U.S. Food and Drug Administration (FDA) to discuss the agency’s response to the New Drug Application (NDA) for Acurox (oxycodone HCl and niacin). The companies and the agency agreed that the NDA should be reviewed by an FDA advisory committee. The agency has not asked the companies to conduct additional clinical trials. Acurox is an orally administered immediate release tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. King and Acura are looking to gain approval of Acurox for the relief of moderate-to-severe pain. Acurox is also designed to discourage some common methods of misuse and abuse. In its complete response letter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CP) ZymoGenetics Files Against King Pharma</title>
		<link>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160</link>
		<comments>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160#comments</comments>
		<pubDate>Sat, 22 Aug 2009 03:11:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Railroads]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Canadian Pacific Railway Limit]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13160</guid>
		<description><![CDATA[ZymoGenetics, Inc. (ZGEN) has filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) requesting the agency to remove King Pharmaceuticals’ (KG) Thrombin-JMI from the market in the interest of patient safety. ZymoGenetics filed the CP based on reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin. Thrombin-JMI is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible. The source material for Thrombin-JMI comes from bovine plasma and lung tissue. The treatment is a key product in King’s portfolio. For the twelve months ended December 31, 2008, Thrombin-JMI accounted for 16.3% of total revenues. As such, the removal of the product from the market would be a major blow for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853</link>
		<comments>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:47:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12853</guid>
		<description><![CDATA[King Pharmaceuticals (KG) reported second quarter results of -32 cents per share, beating the Zacks Consensus Estimate of -38 cents per share. Although revenues increased 12% from the year-ago period, we remain concerned about the declining prescription trends of most of the company&#8217;s key products. Moreover, King faced several regulatory setbacks and is yet to gain approval for its key pipeline candidate, Embeda. The delay in Embeda&#8217;s approval has been frustrating and we expect investor focus to remain on this event. While King is optimistic about gaining approval for Embeda later this year, non-approval would be a major blow. Pipeline setbacks Incorporatedreasing competition, generic threats and declining prescription trends are likely to weigh on the stock. We have an Underperform rating on the stock. Zacks Investment Research View original at: ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

